A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)

China Medical University, China

Status and phase: Enrolling; Phase 2

Conditions: Small Cell Lung Cancer

Treatments: Drug: Chidamide Tablets； PD-L1 Inhibitor (as per chosen drug's prescribing information)；Carboplatin； Etoposide

Study type: Interventional

Funder types: Other

Identifiers

NCT07373964

CSIIT-Q115

Details and patient eligibility

About

This is a Phase II, single-arm, single-center study evaluating Chidamide combined with a PD-L1 inhibitor, carboplatin, and etoposide as first-line therapy in extensive-stage small-cell lung cancer (ES-SCLC) patients. The primary objective is to assess Progression-Free Survival (PFS) per RECIST v1.1. Secondary objectives include Objective Response Rate (ORR), Disease Control Rate (DCR), Duration of Response (DOR), Overall Survival (OS), and safety. Approximately 36 participants will receive induction therapy (Chidamide + chemotherapy + PD-L1 inhibitor) for 4 cycles, followed by Chidamide maintenance until progression or unacceptable toxicity.

Enrollment: 36 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥18 and ≤75 years.
• Histologically confirmed ES-SCLC, unsuitable for local radical therapy.
• No prior systemic therapy for ES-SCLC.
• ECOG performance status 0-1.
• At least one measurable lesion per RECIST v1.1.
• Expected survival ≥3 months.
• Adequate organ function (hematological, hepatic, renal, cardiac).
• Effective contraception from consent until 180 days after last dose.
• For active HBV infection: HBV DNA <2000 IU/mL within 28 days before treatment and on stable antiviral therapy.
• Recovery from prior therapy toxicities to ≤ Grade 1 (except alopecia).
• Signed informed consent.

Exclusion criteria

• Factors significantly affecting oral drug absorption.
• Prior HDAC inhibitor or immune checkpoint inhibitor therapy.
• Known allergy to any study drug component.
• Other malignancy within past 5 years (except certain cured cancers).
• Participation in another clinical trial within 4 weeks.
• Immunodeficiency, HIV positivity, or organ transplant history.
• Uncontrolled cardiovascular disease or QTc >450 ms.
• Pregnancy, lactation, or unwillingness to use effective contraception.
• Other severe comorbid conditions deemed unsafe by investigator.
• History of neurological or psychiatric disorders.
• Any condition making the patient unsuitable per investigator judgment.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

36 participants in 1 patient group

treatment group

Experimental group

Treatment:

Drug: Chidamide Tablets； PD-L1 Inhibitor (as per chosen drug's prescribing information)；Carboplatin； Etoposide